Breaking News

iBio Advances COVID-19 Vaccine Candidate

IBIO-201 induced the production of anti-spike neutralizing antibodies in tests.

By: Contract Pharma

Contract Pharma Staff

iBio Inc., a biotech innovator and biologics contract manufacturing organization, has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection.   iBio previously announced that preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute (IDRI), induced anti-SARS-CoV-2 antibodies. Additional data from cell-based pseudovirus neutralization assay testing demonstrate...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters